Researchers from MRC Laboratory of Medical Sciences and Imperial College London identified a senescence vulnerability tied to GPX4-dependent ferroptosis. In models of melanoma, prostate and ovarian cancer, combining senescence-inducing cancer therapies with GPX4 inhibitors eliminated senescent tumor cells, according to a Nature Cell Biology paper authored by Mariantonietta D’Ambrosio and colleagues. The findings point to a drug strategy that exploits how senescent cells resist death.